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In peripheral nervesMSCs canmodulateWallerian degeneration and the overall regenerative response by acting through paracrine
mechanisms directly on regenerating axons or upon the nerve-supporting Schwann cells. In the present study, the effect of
humanMSCs fromWharton’s jelly (HMSCs), differentiated into neuroglial-like cells associated to poly (DL-lactide-𝜀-caprolactone)
membrane, on nerve regeneration, was evaluated in the neurotmesis injury rat sciatic nerve model. Results in vitro showed
successful differentiation of HMSCs into neuroglial-like cells, characterized by expression of specific neuroglial markers confirmed
by immunocytochemistry and by RT-PCR and qPCR targeting specific genes expressed. In vivo testing evaluated during the healing
period of 20 weeks, showed no evident positive effect of HMSCs or neuroglial-like cell enrichment at the sciatic nerve repair site
on most of the functional and nerve morphometric predictors of nerve regeneration although the nociception function was almost
normal. EPT on the other hand, recovered significantly better after HMSCs enriched membrane employment, to values of residual
functional impairment compared to other treated groups. When the neurotmesis injury can be surgically reconstructed with an
end-to-end suture or by grafting, the addition of a PLC membrane associated with HMSCs seems to bring significant advantage,
especially concerning the motor function recovery.
1. Introduction
Traumatic injuries affecting the central and the peripheral
nervous system are often characterized by very limited recov-
ery of lost functions and severe incapacity. In cases of no sur-
gical treatment, spontaneous nerve regeneration is in many
cases curtailed by scars, neuroma formation, mismatched
nerve fascicles, or extensive splitting of the regrowing axons.
Moreover, peripheral nerve damage is often associated with
neuropathic pain, referred by patients as a more important
reason for poor quality of life than the incomplete functional
recovery [1]. Functional outcome is directly related with the
degree of injury. Peripheral nerve regeneration is worse if
a nerve gap exists, leading to functional impairment and
frequently to neuroma [1, 2]. The time delay between the
instant of traumatic nerve injury and of surgical repair is
also an important factor determining functional outcome for
various reasons [3].
Peripheral nerve neurotmesis is a relatively common type
of traumatic injury affecting the peripheral nervous system.
These constitute a severe nerve damage in which both nerve
fibers and the nerve sheaths suffer disruption and sponta-
neous recovery becomes extremely difficult in cases when
the peripheral nerve is not microsurgically reconstructed [4].
Whenever tension-free suturing is possible, direct end-to-
end repair is the treatment of choice. However, when there
is a nerve gap that resulted from the loss of the nerve tissue,
an autologous nerve graft is typically undertaken, usually
using an expendable sensory nerve, such as the sural nerve.
However, autologous nerve grafting has important disadvan-
tages, the most important being donor site morbidity that
may lead to a secondary sensory deficit and occasionally
neuroma and pain. In addition, no donor and recipient nerve
diameters match often occurs and the fact of using, in most
clinical situations, a sensory nerve to reconstruct a motor
or a motor and sensory nerve might be the basis for poor
functional recovery [5]. In some cases, entubulation can be
used instead of grafting. Numerous experimental trials in
animalmodels demonstrate the efficacy of tube-guides, made
of different biomaterials, in supporting peripheral nerve
regeneration. Some clinical cases also show that tube-guides
can be safely employed in the reconstruction of peripheral
nerves in human patients [6]. In these cases, the nerve
will grow and regenerate from the proximal stump towards
the distal nerve stump, while the ingrowth of fibrous tissue
and neuroma formation are prevented by the tube-guide and
simultaneously, a favorable microenvironment is created for
the Wallerian degeneration and regeneration process during
the healing period [6].
The development of cell-based therapies opened new
venues in tissue regeneration including central andperipheral
nerve system. Considering the peripheral nerve system,
cellular systems are promising therapies to be applied alone
or associated to scaffolds, especially, in neurotmesis injuries
where the surgical reconstruction is not possible without
tension and there is loss of tissue, creating critical defects
of the nerve [6]. Regeneration is a physical process through
which remaining tissues organize themselves to replace
and repair injured or missing tissues in vivo. Stem cells
from different sources are much likely the golden key for
regenerative medicine [7]. Amongst stem cells, mesenchymal
stem cells (MSCs) have become one of the most interesting
targets due to their well-known characteristics. MSCs have a
high plasticity and proliferative and differentiation capacity,
together with promising immunosuppressive properties [6].
Furthermore, nowadays the identification and characteri-
zation of MSCs is well defined by recommendations and
standards stated by the Mesenchymal and Tissue Stem Cell
Committee of the International Society for Cellular Therapy
(ISCT) [8]. The therapeutic effect of MSCs does not simply
reside on their capacity to replace the original cells of
damaged tissues. In fact, MSCs seem capable of secreting
a variety of growth factors and cytokines that modify their
microenvironment and induce the activity of endogenous
progenitor cells within the injured tissue [9, 10]. Also, several
studies demonstrate that MSCs exert a modulatory action
on the inflammatory and immune responses and by these
means contribute to tissue healing [11]. Therefore, the use of
cellular systems is a rational approach for delivering growth-
promoting factors and cytokines at the nerve lesion site [12].
MSCs can be isolated from several tissues, including bone
marrow, skin, periosteum, amniotic fluid, umbilical cord
blood and matrix, and adipose tissue [12]. Bone marrow
represents the most frequently used tissue source of MSCs
and these cells have been used in cell based therapies.
However, as a source of MSCs, the bone marrow has several
disadvantages, like limited number of MSCs available, the
heterologous and nonconsistent nature of bone marrow
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preparations, and the possibility of donor site morbidity,
as well as decreased number of MSCs along the adult life.
For these reasons, it was important to identify alternative
and more primordial MSCs sources that would allow a safe
and controlled ex vivo expansion for potential allogeneic
utilization [12]. Umbilical cord tissue-derived MSCs exhibit
a neuronal phenotype [13–16] and are potentially useful for
the treatment of neurodegenerative diseases [17, 18], again
showing the versatility of this cell source. Interestingly, these
cells are negative for the class II major histocompatibility
complex (MHC) and have low expression of MHC class I
[15], increasing their potential for MSC-based therapies. In
addition, these cells represent a noncontroversial source of
primitivemesenchymal progenitor cells that can be harvested
after birth, cryogenically stored, thawed, and expanded for
therapeutic uses [12, 19]. In the present work, the HMSCs
isolated from the umbilical cord Wharton’s jelly were tested
concerning the nerve regeneration after a neurotmesis injury
surgically reconstructed after an end-to-end and a graft
procedure. Since these HMSCs are not only capable of
differentiating into trilineage mesenchyme cell types, such as
adipocytes, chondrocytes, and osteoblasts [8] but also capable
of differentiating into neuronal-like cells, including astro-
cytes, oligodendrocytes, microglial, neurons, and neuroglial-
like cells [12, 19], HMSCs and in vitro differentiated HMCs
into neuroglial-like cells were used in this study.Morphology,
immunocytochemistry, and DNA-based approaches were
applied to sustain the identity of differentiated HMSCs
into neuroglial-like cells. Regarding immunocytochemistry,
antibodies reactive to growth associated protein 43 (GAP-43),
reactive to glial fibrillary acidic protein (GFAP), and reactive
to neuronal specific nuclear protein (NeuN) were used on
slides with fixed HMSCs. As per DNA-based approaches,
more particularly, RT-PCRandqPCR, the expression of seven
genes, two housekeeping genes (𝛽-actin and GAPDH), and
five genes specific of neuronal cells (GFAP, NeuN, Nestin,
NF-H, and GAP-43) were analyzed. Regarding the target
genes, GFAP stands for glial fibrillary acidic protein, a protein
present in the intermediate filament found in astroglial cells,
cells that support and nourish neurons; NeuN stands for
neuronal specific nuclear protein, a neuronal nuclear antigen
commonly used as a biomarker for neurons; Nestin is a type
VI intermediate filament (IF) protein expressed mostly in
nerve cells where they are implicated in the radial growth
of the axon; NF-H is the heaviest subunit of neurofilaments
(NF) found in neurons, a major component of the neuronal
cytoskeleton, and believed to function primarily to provide
structural support for the axon and to regulate axon diameter;
GAP-43 stands for growth associated protein 43, a protein
expressed at high levels in neuronal growth cones during
development, during axonal regeneration [19].
In order to implant cultured cells like HMSCs into defec-
tive nerves (with axonotmesis and neurotmesis injuries),
there are two main techniques. The cellular system may
be directly injected to the neural scaffold which has been
interposed between the proximal and distal nerve stumps or
around the crush injury (in neurotmesis and axonotmesis
injuries, resp.). In alternative, implant can also be achieved
by preadding the cells to the neural scaffold via injection
or coculture (in most of the cellular systems, it is allowed
to form a monolayer) and then the biomaterial with the
cellular system is implanted in the injured nerve [12, 19]. In
this experimental work a biomaterial commercially available
(Vivosorb) to be used as a vehicle for the undifferentiated and
differentiated cellular system tested in the nerve defects was
used. Biomaterials are known to be able to support cellular
systems to either differentiate into neuroglial-like cells or
to enhance their paracrine effects on the overall regener-
ative process. Concomitantly, biomaterials can be directly
involved in the regenerative process, helping to improve
the motor and sensory functional recovery, shortening the
healing period and avoiding regional muscular atrophy [20,
21]. A suitable biomaterial for nerve conduit must fulfill
several biological and physicochemical requirements and
might be of biological origin or synthetic. Such requirements
include biocompatibility, biodegradability, permeability to
ions and metabolites for the revascularization of the regen-
erated nerve, and biomechanical and surface properties that
enable and modulate cellular systems adhesion [12, 19, 20].
Among synthetic biodegradable materials, poly(DL-lactide-
𝜀-caprolactone) (PLC) attracted particular attention to our
research group [21–25]. The biodegradation rate of PLC is
estimated to be around 16 months and the degradation prod-
ucts of PLC are less acidic, like for instance poly(L-lactide):
poly(glycolide) (PLGA), which may cause less damage to
the surrounding tissue. Also, PLC is transparent facilitating
the correct positioning of the nerve stumps. Previous in
vitro studies have shown that PLC membranes and tube-
guides are biocompatible with nerve cells and may facilitate
nerve cell attachment, differentiation, and growth [21, 22,
26, 27]. Also, in vivo studies have demonstrated that PLC
might improve morphological and functional recoveries, in
axonotmesis and neurotmesis injuries of the rat sciatic nerve,
while the structure of the polymer was still well preserved
after 20 weeks in nerves repaired with PLC [21, 22]. Shin
and colleagues (2009) tested PLC guiding-tubes and two
different synthetic, bioabsorbable biomaterials and compared
their efficacy for the reconstruction of the sciatic nerve with
a reversal autograft. In this case, the PLC tube was, within
the biomaterials, that with the best outcome, which was
even comparable with the efficacy of the autograft [28]. In
the present study the therapeutic value of undifferentiated
human MSCs (HMSCs) isolated from the Wharton’s jelly of
the umbilical cord was tested in vivo or in vitro differentiated
into neuroglial-like cells, together with a poly(DL-lactide-
𝜀-caprolactone) (Vivosorb) membrane, to promote nerve
regeneration in neurotmesis injuries surgically reconstructed
with an epineural end-to-end suture or with an inverted
autograft. A complete functional analysis was performed
during the healing period of 20 weeks, including extensor
postural thrust (EPT) and withdrawal reflex latency (WRL)
tests, for evaluating the motor and nociception function,
respectively. The functional assessment also included the
kinematic analysis of the rat gait during the healing period. A
morphometry analysis of the regenerated nerves was assessed
at week 20. Also, the differentiation capacity of the HMSCs
into neuroglial-like cells was tested in vitro, previously to the
in vivo application.
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Figure 1: Monocultures of HMSCs from Wharton’s jelly over PLC membrane exhibiting a mesenchymal-like shape with a flat polygonal
morphology (a).Monocultures ofHMSCs fromWharton’s jelly over PLCmembrane after 72 h of culture in neurogenicmedium; differentiated
HMSCs (small white arrows) became exceedingly long and there is a formation of typical neuroglial-like cells with multibranches (b)
(magnification: 100x). SEM image of PLC tube-guide with inner diameter highlighted by large white arrow and outer diameter highlighted
by small black arrows (magnification: 250x) (c). SEM image of HMSCs (large black arrow highlighting cell) cultured over a PLC disc
(magnification: 1000x) (d).
2. Materials and Methods
2.1. Poly(DL-lactide-𝜀-caprolactone) (PLC) Membranes.
Poly(DL-lactide-𝜀-caprolactone) (PLC) membranes (Vivos-
orb) were purchased from Polyganics BV, Groningen,
Netherlands (FS01-006/20 Lot: FSA2009092311). Vivosorb
is a flexible bioresorbable polymer film, made of poly(DL-
lactide-𝜀-caprolactone) copolymer which presents retention
of mechanical strength for up to 10 weeks throughout the
critical healing period (Figures 1(c) and 1(d)).
2.2. Cell Culture and In Vitro Differentiation of HMSC from
Wharton’s Jelly Umbilical Cord. Human MSC from Whar-
ton’s jelly umbilical cord (HMSCs) were purchased from
PromoCell GmbH (C-12971, lot-number: 8082606.7). This
established human MSC cell line was preferred for in vivo
testing in rats; since the number of MSCs obtained was
higher in a shorter culture time, it was not dependent on
donors availability and ethic committee authorization, and
the protocol was much less time consuming which was
advantageous for preclinical trials with a large number of
experimental animals. Cryopreserved cells were cultured
and maintained in a humidified atmosphere with 5% CO
2
at 37∘C. Mesenchymal stem cell medium (PromoCell, C-
28010) was replaced every 48 hours. At 90% confluence, cells
were harvested with 0.25% trypsin with EDTA (Gibco) and
passed into a new flask for further expansion. HMSCs at
a concentration of 2500 cells/mL were cultured and after
24 hours cells exhibited 30–40% confluence. Differentiation
was induced with MSC neurogenic medium (PromoCell,
C-28015). Medium was replaced every 24 hours during 3
consecutive days. The formation of neuroglial-like cells was
observed after 24 hours in an inverted microscope (Zeiss,
Germany) (Figures 1(a), and 1(b)).
HMSC cell line (differentiated) from Wharton’s jelly was
studied for cytogenetic analysis at passage 5. When conflu-
ence was reached, culture medium was changed and sup-
plemented with 4𝜇g/mL colcemid solution (stock solution,
Cat. number 15212-012, Gibco). After 4 hours, HMSCs were
collected and suspended in 8mL of 0.075M KCl solution
supplemented with bovine fetal serum (BFS). Then the
suspension was incubated in 37∘C for 35 minutes. After cen-
trifugation (1500 rpm), 8mL of the fixative methanol : glacial
acetic acid at 6 : 1 was added and mixed together, and
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Figure 2: Neuroglial-like cells obtained from HMSCs in vitro differentiated with neurogenic medium exhibiting a positive staining for (a)
GFAP which is a glial cell marker; (b) GAP-43 which is related with axonal outgrowth; and (c) NeuN which is a marker for nucleus of
neurons. Undifferentiated HMSC cells from the Wharton’s jelly presenting a negative staining for (small panel inserted in (a)) GFAP; (small
panel inserted in (b)) GAP-43, and (small panel inserted in (c)) NeuN (magnification: 200x).
the cells were again centrifuged. After 2 rounds of fixation,
2 new rounds were performed with the fixative meth-
anol : glacial acetic acid at 3 : 1. After the last centrifugation,
theHMSC suspensionwas spread onto verywell glass cleaned
slides. Analysis was performed by one scorer on Giemsa-
stained cells.
Intracellular free Ca2+ concentration ([Ca2+]
𝑖
) was mea-
sured in Fura-2-loaded cells by using dual wavelength
spectrofluorometry as previously described [12, 19, 23, 26].
The measurements were performed on undifferentiated
HMSCs after confluence was obtained and on neuroglial-
differentiated HMSCs, cultured on Vivosorb discs in order
to correlate the HMSCs ability to differentiate and survival
capacity in the presence of the Vivosorb membrane (Fig-
ure 1(d)).
2.3. Immunocytochemistry. At passage 3, HMSCs were tryp-
sinized, washed, and resuspended in mesenchymal stem cell
medium (PromoCell, C-28010) at a concentration of 1 × 105
cells/mL. HMSCs were fixed with paraformaldehyde at 4∘C
for 15min and washed with distilled water before perme-
abilization in 0.5% Triton-X100. Non-specific binding was
blocked using blocking solution (PBS containing 1% bovine
serum albumin (BSA)) for 1 hour at room temperature.
HMSCs were then incubated 2 hours at room temperature
with primary antibodies from rabbit against antigrowth
associated protein-43 (GAP-43, 1 : 200) (Chemicon, AB5220)
and against antiglial fibrillary acidic protein (GFAP, 1 : 500)
(Chemicon, AB5804) and from mouse against antineuronal
nuclei (NeuN, 1 : 100) (Chemicon, MAB377). After washing,
HMSCs were incubated 15 minutes with goat anti-rat IgG
(Millipore, AP136P) and goat anti-rabbit IgG (Millipore, 12-
348MN) secondary antibodies. After several washes in PBS,
HMSCs were incubated with horseradish peroxidase (HRP-)
coupled streptavidin for 10min. DAB (diaminobenzidine)
served as chromogen (Figure 2).
2.4. Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR). Reverse transcriptase Polymerase chain reaction (RT-
PCR) and qPCR targeting specific genes expressed by
neuronal cells were performed. For that, primers were de-
signed targeting seven human genes based on the liter-
ature [29–31]. DNA sequences from GAP-43, NF-H, Nestin,
GAPDH, 𝛽-actin, NeuN, and GFAP genes from mice (Mus
musculus), rat (Rattus norvegicus), and human (Homo sapi-
ens) were downloaded from GenBank (http://www.ncbi.nlm
.nih.gov/genbank) and aligned using the Clustal Omega
bioinformatic tool from EMBL-EBI (http://www.ebi.ac.uk/
Tools/msa/clustalo). The primers targeting the human genes
are listed in Table 1. Both differentiated and undifferentiated
HMSC’s cultures were harvested with 0.25% trypsin EDTA
solution (Gibco) and centrifuged at 2000 rpm 4∘C during
5min. Cell pellets were used for total RNA extraction using
an adequate extraction kit, High Pure RNA Isolation kit
(Roche). Briefly, cell pellets were lysed with a lysis buffer and
loaded into a High Pure Filter Tube; DNA was removed with
DNase I enzyme, washed twice on column, and eluted with
100 𝜇L of Elution Buffer. RNA was quantified and its quality
was assessed by using a nanodrop ND-1000 spectropho-
tometer and reads from 220 nm to 350 nm, and then stored
at −80∘C until further use. In the following step, cDNA was
synthesized from the purifiedRNA.To fulfill that issue, the kit
Ready-To-GoYou-Prime First-Strand Beads (GEHealthcare)
was used following the manufacturer instructions. Briefly,
1.5 𝜇g of total RNA was used and diluted in DEPC-treated
water to a 30 𝜇L final volume in a RNase-freemicrocentrifuge
tube, then heated at 65∘C for 10 minutes, and then chilled
in ice; transfer the RNA solution to the kit tube containing
the first-strand reaction mix beads; add 0.2 𝜇g of Oligo(dT)
primer and DEPC-treated water to a 33 𝜇L final volume;
mix the content and incubate at 37∘C for 60 minutes. cDNA
was synthesized and stored at −20∘C until further use. Of
referring that, due to the use of the Oligo(dT) primer, the
synthesized cDNA corresponds to the mRNA present in the
sample at the time of collection. cDNA synthesized from
undifferentiated and differentiatedHMSCswas used to check
the expression of seven genes, two housekeeping genes (𝛽-
actin and GAPDH) and five specific of neuronal cells (GFAP,
NeuN, Nestin, NF-H, and GAP-43). As previously described,
primers were designed in house and then synthesized
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Table 1: List of primers used, target gene, and size of the PCR product.
Primer GenBank target gene PCR product
GFAP hum Fwd: 5󸀠-CCAGCTGCGGGCCAAGGA-3󸀠 NG 008401.1 56 bp
GFAP hum Rev: 5󸀠-GCAGCTCAGCCTGGTAGACG-3󸀠
NeuN hum Fwd: 5󸀠-AGTAGCTGGGAATTATGGA-3󸀠 NM 005598.3 157 bp
NeuN hum Rev: 5󸀠-ATTGGGACAGTAGGAGTCAGA-3󸀠
𝛽-actin hum Fwd: 5󸀠-GGCACCCAGCACAATGAAGA-3󸀠 NM 001101.3 100 bp
𝛽-actin hum Rev: 5󸀠-CTGGAAGGTGGACAGCGAGGC-3󸀠
GAPDH hum Fwd: 5󸀠-CCCTGCCTCTACTGGCGC-3󸀠 XM 005253678.1 60 bp
GAPDH hum Rev: 5󸀠-TTCCCGTTCAGCTCAGGG-3󸀠
Nestin hum Fwd: 5󸀠-GGCAGCGTTGGAACAGAGGTTGGA-3󸀠 NM 006617.1 164 bp
Nestin hum Rev: 5󸀠-ACATCTTGAGGTGCGCCAGCT-3󸀠
NF-H hum Fwd: 5󸀠-GTGGTGGAGAAGTCTGAGAA-3󸀠 NM 021076.3 176 bp
NF-H hum Rev: 5󸀠-GGAGACTTTGTTTCTTCTTC-3󸀠
GAP-43 hum Fwd: 5󸀠-TGCTGTGCTGTATGAGAAGAACC-3󸀠 NM 001130064.1 160 bp
GAP-43 hum Rev: 5󸀠-GCAAGGGCTGAGGTGTTATGA-3󸀠
in an external laboratory (MWG Operon, Germany). Upon
arrival, primers were rehydrated in DNase/RNase free water
in a concentration of 100 pmol/𝜇L. Quantitative PCR (qPCR)
was performed in a iCycler iQ5 (BioRad) apparatus using the
iQ SYBR Green Supermix (BioRad). Each pair of primers
targeting a gene was used to analyze its expression in
the differentiated and undifferentiated HMSC’s cDNA, in
triplicate, along with a negative control.The plates containing
the mix targeting the seven genes for both types of cells
were submitted to the following cycles of temperatures:
95∘C during 4 minutes, 35 cycles comprising 95∘C during
20 seconds, 55∘C during 20 seconds, and 72∘C during 20
seconds endingwith real-time acquisition and final extension
of 75∘C for 7minutes. After cycling temperatures, the number
of cycle threshold for each well was recorded. The plate
containing the amplified genes or qPCR products was kept
in ice and observed in a 2% agarose gel to check and
reinforce the identity of the amplicons. Briefly, 2 gr ofNuSieve
3 : 1 Agarose (Lonza) was mixed with 100mL Tris-Acetate-
EDTA buffer, melted, mixed with ethidium bromide in a
final concentration of 0.2𝜇g/mL, and loaded in a horizontal
electrophoresis apparatus. After solidification, 15𝜇L of the
qPCRproducts was loaded in the agarosewells and submitted
to a 120V potential difference during 40 minutes to separate
the amplicons. Gel was then observed under UV light and
pictures were recorded using the GelDoc 2000 (BioRad) and
Quantity One software (BioRad).
2.5. Surgical Procedure. All animal testing procedures were
carried out in conformity with the Directive 2010/63/EU
of the European Parliament and with the approval of the
Veterinary Authorities of Portugal in accordance with the
EuropeanCommunities Council Directive of November 1986
(86/609/EEC). Humane end points were followed in accor-
dance to theOECDGuidanceDocument on the Recognition,
Assessment, and Use of Clinical Signs as Humane Endpoints
for Experimental Animals Used in Safety Evaluation (2000).
For the in vivo testing, Sasco Sprague adult rats (Charles River
Laboratories, Barcelona, Spain) were divided into groups of
6 animals each. All animals were housed in a temperature
and humidity controlled room with 12-12 hours light/dark
cycles, two animals per cage (Makrolon type 4, Tecniplast,
VA, Italy), and were allowed normal cage activities under
standard laboratory conditions. The animals were fed with
standard chow and water ad libitum. Adequate measures
were taken to minimize pain and discomfort taking in
account human endpoints for animal suffering and distress.
Animals were housed for two weeks before entering the
experiment. For surgery, animals were placed prone under
sterile conditions and the skin from the clipped lateral right
thigh scrubbed in a routine fashion with antiseptic solution.
The surgeries were performed under an M-650 operating
microscope (Leica Microsystems, Wetzlar, Germany). Under
deep anesthesia (ketamine 90mg/Kg; xylazine 12.5mg/Kg,
atropine 0.25mg/Kg i.m.), the right sciatic nerve was exposed
through a skin incision extending from the greater trochanter
to themidthigh distally followedby amuscle splitting incision
[22]. The right sciatic nerve transection (neurotmesis) injury
was performed, immediately above terminal nerve ramifi-
cation, with a straight microsurgical scissor. A group of 6
animals was used as control and with the sciatic nerve being
left intact (Group 1:Control). In Group 2 the sciatic nerve was
transected and left unrepaired, with the nerve stumps sutured
to surrounding tissue in order to prevent nerve regeneration
(Group 2: Gap). In Group 3, immediate cooptation with 7/0
monofilament nylon epineural sutures of the 2 transected
nerve endings was performed (Group 3: End-to-End). In
Group 4, the two endings of nerve transection were imme-
diately sutured with a 7/0 monofilament nylon suture and
enwrapped in a PLC (Vivosorb) membrane covered with a
monolayer of nondifferentiated HMSCs (Group 4: End-to-
EndPLCCellnonDif ); in Group 5, the two endings of nerve
transection were immediately sutured as the previous group
and enwrapped in a PLC (Vivosorb) membrane covered
with a monolayer of differentiated HMSCs (Group 5: End-
to-EndPLCCellDif ). In the last three groups, the sciatic
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nerve was bisected immediately above the terminal nerve
ramification and at a 10mm distal point. The resulting
nerve graft, with a length of 10mm, was inverted 180∘ and
sutured with 7/0 monofilament nylon. One group was used
as control for the graft (Group 6: Graft); in another group
the graft was enwrapped in a PLC (Vivosorb) membrane
covered with a monolayer of non-differentiated HMSCs
(Group 7: GraftPLCCellnonDif ) and in the last of the groups,
the graft was enwrapped in a PLC (Vivosorb) membrane
covered with a monolayer of differentiated HMSCs (Group
8: GraftPLCCellDif ) (Figures 1(a), 1(b), 1(c), and 1(d)). No
local or systemic signs of rejection or foreign body were
observed in the experimental animals transplanted with PLC
membranes and HMSCs (undifferentiated and differenti-
ated). No immunosuppressive treatment was given to any of
the experimental animals during the entire study.
2.6. Functional Assessment. All animals were tested preoper-
atively (week 0) and every week until week 12 and every 2
weeks until the end of follow-up time (20 weeks). Animals
were gently handled and tested in a quiet environment to
minimize stress levels.
2.6.1. Motor Performance and Nociceptive Function. The
extensor postural thrust (EPT) was originally proposed by
Thalhammer and collaborators, in 1995 [32] as a part of the
neurological recovery evaluation in the rat after sciatic nerve
injury. For this test, the entire body of the rat, excepting the
hind-limbs, was wrapped in a surgical towel. Supporting the
animal by the thorax and lowering the affected hind-limb
towards the platform of a digital balance, elicits the EPT. As
the animal is lowered to the platform, it extends the hind-
limb, anticipating the contact made by the distal metatarsus
and digits. The force in grams (g) applied to the digital
platform balance (model TM560; Gibertini, Milan, Italy) was
recorded. The same procedure was applied to the contralat-
eral, unaffected limb. Each EPT test was repeated 3 times and
the average result was considered. The normal (unaffected
limb) EPT (NEPT) and experimental EPT (EEPT) values
were incorporated into (1) to derive the functional deficit
(varying between 0 and 1), as described byKoka andHadlock,
in 2001 [33]. Consider
Motor Deficit = NEPT − EEPT
NEPT
. (1)
To assess the nociceptive withdrawal reflex (WRL), the
hotplate test was modified as described by Masters and
collaborators [34]. The rat was wrapped in a surgical towel
above its waist and then positioned to stand with the affected
hind paw on a hot plate at 56∘C (model 35-D, IITC Life
Science Instruments, Woodland Hill, CA). WRL is defined
as the time elapsed from the onset of hotplate contact to
withdrawal of the hind paw and measured with a stopwatch.
Normal rats withdraw their paws from the hotplate within
4.3 s or less [35]. The affected limbs were tested 3 times, with
an interval of 2min between consecutive tests to prevent
sensitization and the three latencies were averaged to obtain
a final result [36]. If there was no paw withdrawal after 12 s of
stimulation, the heat stimulus was removed to prevent tissue
damage, and the animal was assigned the maximal WRL of
12 s [37, 38].
2.6.2. Kinematic Analysis. Ankle kinematics was carried out
before nerve injury (week 0), and at the 20-week follow-
up time. Animals walked on a Perspex track with length,
width, and height of, respectively, 120, 12, and 15 cm. In order
to ensure locomotion in a straight direction, the width of
the apparatus was adjusted to the size of the rats during
the experiments. The rats’ gait was video recorded at a rate
of 300 images per second (CASIO EXILIM PRO EX-F1,
Japan). The camera was positioned at the track’s half-length
where gait velocity was steady and 1m distant from the track
obtaining a visualization field of 14 cmwide.The video images
were stored in a computer hard disk for latter analysis using
an appropriate software APAS (Ariel Performance Analysis
System, Ariel Dynamics, SanDiego, USA). 2D biomechanical
analysis (sagittal plan) was carried out applying a two-
segment model of the ankle joint, adopted from the model
firstly developed by [24].The rats’ ankle anglewas determined
using the scalar product between a vector representing the
foot and a vector representing the lower leg. With this model,
positive and negative values of position of the ankle joint
(𝜃∘) indicate dorsiflexion and plantarflexion, respectively. For
each step cycle the following time points were identified,
initial contact (IC), opposite toe off (OT), and heel rise (HR)
and toe-off (TO) [24, 39, 40], and were time normalized for
100% of step cycle.The normalized temporal parameters were
averaged over all recorded trials. A total of six walking trials
for each animal with stance phases lasting between 150 and
400ms were considered for analysis, since this corresponds
to the normal walking velocity of the rat (20–60 cm/s) [24,
41, 42].
2.7. Histology and Scanning Electron Microscopy (SEM).
Nerve samples (10-mm-long sciatic nerve segments distal to
the crush site and from un-operated controls) were processed
for histological analysis of myelinated nerve fibers [43].
Fixation was carried out using 2.5% purified glutaraldehyde
and 0.5% saccarose in 0.1M sorensen phosphate buffer for
6–8 hours and resin embedding was carried out following
Glauerts’ procedure [44]. Series of 2 𝜇m thick semithin
transverse sections were cut using a Leica Ultracut UCT
ultramicrotome (Leica Microsystems, Wetzlar, Germany)
and stained by Toluidine blue. Histological observation was
carried out on a DM4000B microscope equipped with a
DFC320 digital camera and an IM50 image manager system
(Leica Microsystems, Wetzlar, Germany).
Prior to scanning electron microscopy (SEM) analysis,
the HMSCs cultured on PLC discs and the PLC tube-guide
without HMSCs (Figures 1(c) and 1(d)) were first fixed with
1.5% glutaraldehyde in 0.14M sodium cacodylate buffer (pH
7.3) for 2 h at 4∘C. Afterwards, the PLC samples with and
without the HMSCs were dehydrated using graded ethanol
solutions from 60% to 100%, 5 minutes each, and subjected
to critical point drying. Finally, the samples were mounted
on aluminum stubs using double-side adhesive tape and
sputter coated with gold/palladium thin film, using the
SPI Module Sputter Coater equipment for 100 seconds and
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with a 15mA current. The SEM/EDS exam was performed
using a high resolution (Schottky) Environmental Scanning
Electron Microscope with X-Ray Microanalysis and Elec-
tron Backscattered Diffraction analysis: Quanta 400 FEG
ESEM/EDAX Genesis X4M.
2.8. Statistical Analysis. Data was analysed using two-way
mixed factorial ANOVA (General Linear Model). The design
included two between-subjects variables with two conditions
or levels (grafting versus nongrafting) and three conditions
(no-cells, undifferentiated cells, and differentiated cells) and
one within-subjects factor that included the time-repeated
functional measures. Mauchly’s test was used to assert
sphericity and, if necessary, degrees of freedom correction
was introduced using the Greenhouse-Geisser’s epsilon.
Simple planned contrasts (General Linear Model, simple
contrasts) were used to compare data pooled across all
experimental groups during recovery against preoperative
data. Pairwise comparisons between groups were carried
out by the HSD Tukey’s test. All statistical procedures were
performed with the statistical package SPSS (version 17.0,
SPSS, Inc). Data is presented as mean ± standard deviation of
themean (SD) or asmean± standard error of themen (SEM).
3. Results
3.1. Confirmation of HMSCs Differentiation into Neuroglial-
Like Cells by Immunocytochemistry and Karyotype Analysis.
The phenotype of HMSCs was assessed by PromoCell. Rigid
control of quality tests was performed for each PromoCell’s
lot of HMSCs. HMSCs were tested for cell morphology,
adherence rate and viability. Furthermore, each cell lot was
characterized by flow cytometry analysis for a comprehensive
panel of markers, such as PECAM (CD31), HCAM (CD44),
CD45, and Endoglin (CD105). The HMSCs exhibited a
mesenchymal-like shape with a flat and polygonal morphol-
ogy. During expansion the cells became long spindle-shaped
and colonized the whole culturing surface (Figure 1(a)). After
72 hours of culture in neurogenic medium, we observed a
morphological change. The cells became exceedingly long
and there was a formation of typical neuroglial-like cells
with multibranches and secondary branches (Figure 1(b)).
Initially, the testing of differentiation into MSCs neuroglial-
like cells was based on the expression of typical neuronal
markers by immunocytochemistry, such as glial fibrillary
acidic protein (GFAP), growth-associated protein (GAP)-43,
and neuronal specific nuclear protein (NeuN). Undifferen-
tiated HMSCs were negatively labeled for GFAP, GAP-43,
and NeuN (inserted panels in Figures 2(a), 2(b), and 2(c)).
After 72 hours of differentiation, HMSCs became positively
stained for GFAP (Figure 2(a)) and GAP-43 (Figure 2(b)),
and all nuclei of neuroglial-like cells were also positive for
NeuN, demonstrating successful differentiation of HMSCs
into neuroglial-like cells (Figure 2(c)).
Undifferentiated HMSCs exhibited a normal star-like
shape with a flat morphology (Figures 1(a) and 1(d)).
After in vitro differentiation, HMSCs morphology changed
into typical neuroglial-like pattern with multibranches and
secondary branches (Figure 1(b)). Giemsa-stained cells of
differentiated HMSC cell line at passage 5 were analyzed for
cytogenetic characterization. However, no metaphases were
found; therefore, the karyotype could not be established.
However, the karyotype of undifferentiated HMSCs was
determined previously and no structural alterations were
found demonstrating absence of neoplastic characteristics in
these cells, as well as chromosomal stability to the cell culture
procedures [45].
3.2. Confirmation of HMSCs Differentiation into Neuroglial-
Like Cells by RT-PCRAnalysis. Both differentiated and undif-
ferentiated HMSCs were harvested and their RNA purified
and converted to cDNA using adequate procedures. Primers
targeting typical neuronal markers, two housekeeping genes
(𝛽-actin and GAPDH), and five specific of neuronal cells
(GFAP, NeuN, Nestin, NF-H and GAP-43) were used to
support the differentiation into MSCs neuroglial-like cells
(Table 1).
In the following (Figure 3), the average of Ct values
and the agarose gel of the PCR products from experiments
over the undifferentiated HMSCs is shown. In these cells,
the molecular analysis showed a very small amplification of
GFAP gene, absence of amplification of the NF-H and GAP-
43 genes, and reasonable amplification of NeuN, 𝛽-actin,
GAPDH, and Nestin genes. Amplification of a given gene is
correlated with its expression seeing that the template DNA
is the one generated from mRNA.
In Figure 4, the same results are shown now for the
differentiated HMSCs. In this case, the molecular analysis
shows a similar amplification for NeuN, 𝛽-actin, GAPDH,
and Nestin genes, like it was observed with undifferentiated
HMSCs, but now an increase in the GFAP, NF-H, and GAP-
43 gene expression is perceived. As indicated in Figure 4, this
implies a reduction in Ct values.
3.3. Functional Analysis
3.3.1. Nociceptive Function Evaluated by Withdrawal Reflex
Latency (WRL). Figure 5(a) and Table 3 (see Supplemen-
tary Material available online at http://dx.doi.org/10.1155/
2014/302659) present the data for theWRLduring the healing
period of 20 weeks. As expected, during the first week (week
1) following sciatic nerve transection and repair, animals were
unable to respond to the hot stimulus, indicating complete
loss of thermal and nociceptive sensitivity at the sole of the
foot. Signs of recovery of foot’s withdrawal response began
at week 2 following the sciatic nerve injury. Thereafter, the
WRL steadily improved during the 20-week recovery time
although without recovering its normal value of less than
4 seconds (simple contrasts, 20 weeks versus pre-injury;
𝑃 < 0.05). Anyway, the WRL at week 20 for the treated
groups was almost in the normal value range. At week 20,
the mean WRL of the End-to-EndPLCCellnonDif and End-
to-EndPLCCellDif group was 5.40 ± 1.56 and 7.32 ± 3.43
seconds, respectively. Concerning the graft groups where the
PLC membrane associated to the cellular system the WRL
mean values were 5.41 ± 0.46 and 6.54 ± 2.10 seconds,
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Gene Ct average PCR product
GFAP 29.3
NeuN 24.4
14.4
GAPDH 15.1
Nestin 24.1
28.6
29.7
b-actin
NF-H
GAP-43
56bp
157bp
100 bp
60bp
164bp
176bp
160bp
(a)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
(b)
Figure 3: In this figure average of Ct values (a) and agarose gel profile of the amplification of the selected genes from the undifferentiated
HMSCs (b) are shown. Agarose gel of the undifferentiated HMSCs’ gene expression: lane 1 to 3, duplicates of GFAP gene and negative; lane
4 to 6, duplicates of NeuN gene and negative; lane 7 to 9, duplicates of b-actin gene and negative; lane 10, 50 bp DNA ladder; lane 11 to 13,
duplicates of GAPDH gene and negative; lane 14 to 16, duplicates of Nestin gene and negative; lane 17, 50 bp DNA ladder; lane 18 to 20,
duplicates of NF-H gene and negative; lane 21 to 23, duplicates of GAP-43 gene and negative; lane 24, 50 bp DNA ladder.
Gene Ct average PCR product
GFAP 23.5
NeuN 25.0
16.1
GAPDH 16.3
Nestin 25.3
23.8
24.7
𝛽-Actin
NF-H
GAP-43
56bp
157bp
100 bp
60bp
164bp
176bp
160bp
(a)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
(b)
Figure 4: In this figure the average of Ct values (a) and agarose gel profile of the amplification of the selected genes from the differentiated
HMSCs (b) are shown. Agarose gel of the gene expression of differentiatedHMSCs: lane 1 to 3, duplicates of GFAP gene and negative; lane 4 to
6, duplicates of NeuN gene and negative; lane 7, 50 bpDNA ladder; lane 8 to 10, duplicates of 𝛽-actin gene and negative; lane 11 to 13, duplicates
of GAPDH gene and negative; lane 14, 50 bp DNA ladder; lane 15 to 17, duplicates of Nestin gene and negative; lane 18 to 20, duplicates of
NF-H gene and negative; lane 21, 50 bp DNA ladder; lane 22 to 24, duplicates of GAP-43 gene and negative.
for GraftPLCCellnonDif and GraftPLCCellDif group, respec-
tively. Differences in WRL recovery were found both as a
result of grafting [𝐹
(1,31)
= 7.765; 𝑃 < 0.01] and of HMSCs
application [𝐹
(2,31)
= 14.112; 𝑃 < 0.001]. In particular, WRL
recovered faster and better in animals treatedwith direct end-
to-end repair (End-to-End, End-to-EndPLCcellnonDif, and
End-to-EndPLCcellDif groups) compared to those receiv-
ing a graft (Graft, GraftPLCcellnonDif, and GraftPLCcellDif
groups). Also, animals treated with differentiated (𝑃 < 0.001)
and undifferentiated (𝑃 < 0.005) HMSCs showed slight
worstWRL response, comparedwith animalswithout cellular
treatment. Untreated animals (Gap group) showed no signs
of recovery of the WRL response during the healing period
of 20 weeks (Figure 5(a) and Table 3, supplementary data).
3.3.2. Motor Performance by Measuring Extensor Postural
Thrust (EPT). Immediately following sciatic nerve transec-
tion, all animals presented a severe motor deficit demon-
strated by a virtual complete loss of EPT response in the
affected hind limb (Figure 5(b) and Table 4, supplementary
data). During the healing period of 20 weeks, the abnormal
EPT response improved to some degree in all surgically
treated animals although force output remained diminished
at the ending of the followup (simple contrasts, 20 weeks
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Figure 5:Mean withdrawal reflex latency (WRL) and extensor postural thrust (EPT) results for 20 weeks followup. Values in seconds (s) were
obtained performing withdrawal reflex latency (WRL) test to evaluate the nociceptive function (a). Values of motor deficit were obtained
performing extensor postural thrust (EPT) test (b).This test has been performed preoperatively (week 0) at week 1, week 2, and every 2 weeks
after the surgical procedure until week 20, when the animals were sacrificed for morphological analysis. Data displayed as mean ± SEM.
versus preinjury; 𝑃 < 0.001). At week 20, the mean EPT
of the End-to-EndPLCCellnonDif and End-to-EndPLCCellDif
group was 0.19 ± 0.17 and 0.64 ± 0.27, respectively. Concern-
ing the graft groups where the PLC membrane associated to
the cellular system the WRL mean values were 0.13 ± 0.08
and 0.51±0.19, forGraftPLCCellnonDif andGraftPLCCellDif
group, respectively.
The rate of recovery, but not the extent, of the EPT
response during recovery was affected by application of
HMSCs cells. [𝐹
(2,31)
= 28.778; 𝑃 < 0.001] but not due to
grafting [𝐹
(1,31)
= 0.271; 𝑃 > 0.1, non-significant]. Pairwise
comparisons showed differences between EPT responses in
animals that did not receive the cellular treatment, compared
to those treated with undifferentiated (𝑃 < 0.05) and differ-
entiated HMSCs (𝑃 < 0.001). Differences in EPT response
between animals treated with undifferentiated and differenti-
atedHMSCswere also significant (𝑃 < 0.001). An interaction
effect on EPT responses could be found involving the type of
nerve repair (i.e., direct end-to-end repair or grafting) and
the application of HMSCs [𝐹
(2,31)
= 4.910; 𝑃 < 0.05]. Pooled
EPT data suggests that undifferentiated HMSCs, but not
differentiated HMSCs, enhanced EPT recovery in animals
that were specifically treated with autologous sciatic nerve
graft, thus helping in minimizing the negative consequences
of grafting in functional outcome. Also, data suggests that
undifferentiated HMSCs, but not differentiated HMSCs,
enhanced EPT recovery in animals that were specifically
treated with an end-to-end suture (Figure 5(b) and Table 4,
supplementary data).
3.3.3. Kinematic Analysis. The angle and angular velocity
of the ankle joint (Figures 6(a) and 6(b) and Table 2)
during the stance phase of the step cycle were measured at
the end of the study (week 20).Thesemeasures were collected
also in the uninjured control rats. Regarding sciatic-injured
animals, no changes in ankle angle could be seen between
the different sciatic nerve-treated experimental groups and
between treated groups and the control group, irrespectively
of the specific time instant of the stance phase considered
(Figure 6(a), Table 2).
Regarding ankle angular velocity, differences between
the experimental groups could be found at HR [𝐹
(6,33)
=
10.414; 𝑃 < 0.001] and TO [𝐹
(6,33)
= 2.542; 𝑃 < 0.05] but
not at IC [𝐹
(6,33)
= 1.311; 𝑃 > 0.1, non-significant] and OT
[𝐹
(6,33)
= 1.776; 𝑃 > 0.1, non-significant]. At HR, ankle
velocity was significantly altered in the Gap group compared
with the End-to-EndPLCCellDif, GraftPLCCellnonDif, and
GraftPLCCellDif groups (𝑃 < 0.05). Also at HR, significant
changes in ankle velocity could be seen for every group of
sciatic nerve-injured animals compared with intact animals.
Similar results were found at TO, where ankle velocity in
sciatic nerve-injured animals differed from that of intact
animals. However, at TO ankle velocity was similar in every
group of sciatic nerve-injured animals (Figure 6(b), Table 2).
3.4. Sciatic NerveHistology. Histological analysis on semithin
sections showed that nerve fiber regeneration occurred in all
repaired nerves. In comparison to controls (Group 1,Control)
(Figure 7), in all repaired nerves regenerated fibers showed
small axons with thin myelin sheaths and microfasciculation
(Figures 8(a), 8(b), 8(c), and 8(d)). Microfasciculation was
more evident in the graft repaired groups (GraftPLCCellnon-
Dif andGraftPLCCellDif ) (Figures 8(c) and 8(d)) in compari-
son to End-to-End treated groups (End-to-EndPLCCellnonDif
and End-to-EndPLCCellDif ) (Figures 8(a) and 8(b)). From a
histological point of view, the comparison between treatment
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Figure 6: Kinematic plots in the sagittal plane for angular position (∘) (a) and for angular velocity (∘/s) (b) as it moves through the stance
phase, obtained at week 20 after the neurotmesis injury. The mean of each group is plotted (𝑁 = 6).
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Figure 7: Histological appearance of a normal rat sciatic nerve
(magnification: 1000x).
with undifferentiated and differentiated HMSC did not show
clear differences both after end-to-end (Figures 8(a) and 8(b))
and graft (Figures 8(c) and 8(d)) nerve reconstruction.
4. Discussion
Tissue engineering focusing on the in vitro fabrication of
autologous, living tissues with the potential of regeneration
is a promising scientific and clinical field. Peripheral nerve
regeneration should include a multidisciplinary team able
to develop biomaterials, to develop cell therapies, and to
elaborate in vitro analysis and preclinical trials concerning
animal welfare and themost appropriate animalmodel before
the clinical trials and clinical application approval [46].
Transected peripheral nerves can regenerate spontaneously
providing the connection between the proximal and distal
severed stumps. In cases where there is no substantial nerve
tissue loss, surgical treatment consists in direct end-to-end
suturing of the nerve ends [47–51]. However, in spite of
the progress achieved with microsurgical nerve repair, the
outcome of nerve reconstruction is still far from being
optimal, concerning inmost of the clinical cases, a poor func-
tional recovery [52]. Since during the regeneration process,
axons require neurotrophic support, they could benefit from
the presence of a cellular system capable of responding to
stimuli of the local environment during axonal regeneration,
producing important growth factors and cytokines. In case of
loss of substance a nerve autograft procedure, usually using
expendable sensory nerves, is required [53–55]. However,
the nerve autograft leads to donor site morbidity and sec-
ondary sensory deficit and occasionally neuroma and pain.
In addition, no donor and recipient nerve diameters match
often occurs and the fact of using in most clinical situations,
a sensory nerve to reconstruct a motor or a motor and
sensory nerve, might be the basis for poor functional recov-
ery [5, 56]. Alternatives to peripheral nerve grafts include
cadaver nerve segments allografts, end-to-side neurorrhaphy,
or entubulation by means of autologous nonnervous tissues
such as vein or muscles [54, 57–61]. Therefore, one of the
scientific challenges in the past thirty years has been to find
an alternative to the autologous nerve graft [60]. The use of
a nerve conduit (i.e., a tubular structure designed to bridge
the gap of a sectioned nerve, protect the nerve from the
surrounding tissue, and guide the regenerating axons into
the distal nerve stump) is the most popular alternative to
nerve autografts; yet, conduits can also play an important
role as a vehicle for neurotrophic factors and cellular systems
[3, 21, 23, 26, 54, 57–59, 62–65].
In a previous study, the therapeutic value of HMSCs on
rat sciatic nerve after axonotmesis injury associated to the
same PLCmembrane was evaluated (Vivosorb). Also, in vitro
characterization of the cellular system cultured on PLC discs
(Vivosorb) was carried out bymeans of nuclear magnetic res-
onance (NMR) analysis, immunocytochemistry, and intra-
cellular ionic calcium concentration measurements using the
epifluorescence technique. During HMSCs expansion and
differentiation into neuroglial-like cells, the analysis of the
culturemedium, byNMR,was performed in order to evaluate
the metabolic profile of these cells. Also, it was necessary to
ascertain that PLC membranes were capable of supporting
the expansion anddifferentiation ofHMSCs.Thiswas accom-
plished mainly by assessing [Ca2+]
𝑖
, using epifluorescence
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Figure 8: Histological appearance of regenerated nerve fiber treated with undifferentiated and differentiated HMSC: End-to-
endPLCcellnonDif (a), End-to-endPLCcellDif (b), GraftPLCcellnonDif (c), and GraftPLCcellDif (d) (magnification: 1000x).
technique and the Fura-2AM probe, of undifferentiated and
neuroglial-differentiated HMSCs. The Vivosorb membrane
proved to be adequate to be used as scaffold associated
with undifferentiated HMSCs or neuroglial-differentiated
HMSCs, so that in vivo studies could be pursued in models
of severe nerve injury, such as in the present study [19]. The
same results were obtained in the present experimental work,
considering the [Ca2+]
𝑖
, measurements using epifluorescence
technique with Fura-2AM probe.
In this study, in vitro results demonstrated successfully the
HSMCs differentiation into neuroglia-like cells, as demon-
strated by changes in cell morphology and positive staining
for the specific neuroglialmarkersGFAP,GAP-43, andNeuN.
Previously, it was demonstrated byNMR, thatHMSCs expan-
sion was glycolysis-dependent but that the differentiation
of these cells required the switch of the metabolic profile
to oxidative metabolism. Simultaneously, in vivo studies in
a sciatic nerve crush rat model showed improvement in
regenerated sciatic nerve’s morphology, such as increased
myelin sheath thickness, in animals treated with trans-
planted undifferentiated and differentiated HMSCs, which
was accompanied also by enhanced recovery of motor and
sensory function [19].
Peripheral nerve crush injuries are appropriate to inves-
tigate the cellular and molecular mechanisms of peripheral
nerve regeneration and to assess the role of different factors
in the regeneration process [66]. Nerve crush injury is also a
well-established model in experimental regeneration studies
to investigate the impact of various pharmacological treat-
ments [26, 67, 68] and should be used before testing therapeu-
tic approaches in a more serious lesion, like neurotmesis.The
present study intended to confirm the ability of PLC mem-
branes together with undifferentiated and in vitro differenti-
ated HMSCs to promote nerve regeneration and to improve
functional recovery even when nerves are surgically treated
by epineural end-to-end suture or autologous grafting. Nerve
histology demonstrated successful nerve regeneration of the
transected and repaired sciatic nerves although the extent of
such regeneration was somewhat limited. Regenerated axons
and nerve fibers were small in diameter and their numberwas
clearly diminished in comparison with uninjured nerves. Not
surprisingly, such changes in morphology were more severe
in sciatic nerves treated with the autologous graft and the
cellular system (GraftPLCCellnonDif and GraftPLCCellDif
groups) compared with the direct end-to-end suture and
the cellular system (End-to-EndPLCCellnonDif and End-to-
EndPLCCellDif ). The use of PLC membranes enwrapping
the repaired sciatic nerves could not significantly alter the
degree of nerve regeneration. Similarly, coating the sciatic
nerves at the injury site with undifferentiated or differen-
tiated HMSCs could not significantly modify the extent of
nerve regeneration. These results should be confirmed by
histomorphometric analysis, which unfortunately was not
possible to be performed in this study. The results confirmed
the results obtained previously by Ga¨rtner et al., 2013 [19],
where themyelin sheathwas thicker in the regenerated nerves
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of HMSCs-treated animals, suggesting that HMSCs might
exert their positive effects on Schwann cells, the key element
in Wallerian degeneration and consequent axonal regener-
ation and explaining the functional recovery improvement,
obtained also in the present work. As a matter of fact, regard-
ing functional outcome, the use of undifferentiated HMSCs
modestly improved recovery ofmotor function in the affected
hind-limb when in those cases an autologous graft was used
to bridge the gap of the transected sciatic nerve. At this
point, the mechanisms by which undifferentiated, but not
differentiated, HMSCs might enhance functional recovery
are not identifiable. For that reason, experiments of RT-PCR
were performed with undifferentiated and in vitro differen-
tiated HMSCs in this experimental work. According to the
results of RT-PCR, undifferentiated HMSCs cells in vitro
secreted several factors that can aid in nerve regeneration.
Consistent with the immunocytochemistry observations in
which the antibodies did not recognize GFAP, NF-H, and
GAP-43 proteins in the undifferentiatedHMSCs in the slides,
the molecular analysis showed a small expression of GFAP
gene and absence of expression of the NF-H and GAP-43
genes in these same undifferentiated cells. In fact, the small
detection of the GFAP gene expression may be due to the
high sensitivity of the molecular tests in comparison with
immunocytochemistry tests. Moreover, the expression of the
remaining genes, NeuN, 𝛽-actin, GAPDH, and Nestin, was
also observed in undifferentiated HMSCs. The expression of
the housekeeping genes, 𝛽-actin and GAPDH, is expected to
occur. As per the NeuN and Nestin gene, the observation of
its expression in undifferentiated HMSCs is not new; Bertani
et al. [69] showed that na¨ıve MSCs express at a constitutive
level NeuN gene, which increases when these cells are
chemically induced to differentiate to preneuronal cells. Fur-
thermore, Woodbury et al. [70] compared gene expression
profiles before and afterMSC induction for a number of germ
layers and observed that even before neuronal induction,
MSC population, and clonal lines expressed a mixture of
mesodermal, germinal, endodermal, and ectodermal genes,
including several genes whose expression was thought to be
restricted to neuronal cells. Molecular analysis on these same
genetic markers over the differentiated HMSCs showed an
increase in the expression ofGFAP,NF-H, andGAP-43 genes.
These genes were not expressed, or expressed at very low lev-
els, in the undifferentiated HMSC’s transcriptome. Overall,
these results support the effective in vitro differentiation of
HMSCs into neuron-like cells.
HMSCs isolated from Wharton’s jelly of the umbilical
cord and delivered through PLC membranes might improve
clinical outcome especially after trauma to sensory nerves,
particularly in the cases of nerve injuries with significant
loss of nervous tissue, requiring entubulation or grafting.
When the neurotmesis injury can be surgically reconstructed
with an epineural end-to-end suture without tension or by
grafting, the addition of a PLC membrane associated with
undifferentiated HMSCs seems to bring significant advan-
tage, especially concerning themotor function recovery, basi-
cally by the secretion of local growth factors and cytokines
secretion.
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